The vanilla in your favorite bakery cupcake was probably made with petrochemicals. Lets ferment it ... [+] instead.
The demand for natural products is growing, along with consumers increasing attention to the environment and their health. Consumers are seeking brand alternatives that help them make better, more responsible choices, whether to reduce landfill waste or select healthier ingredients.
Companies like General Mills, Hersheys, and Nestl have heard the message and vowed to eliminate artificial ingredients from foods and replace them with natural ingredients. So say goodbye to your blue Trix cereal and artificially flavored sodas.
The problem is, there isnt enough natural to go around.
Take vanilla, for example, the most popular flavor on the planet. The flavor comes from a molecule called vanillin, the main compound extracted from the vanilla bean. According to Chemical & Engineering News, about 85% of vanillin is chemically synthesized. Less than 1% actually comes from real vanilla, which involves arduous hand cultivation and harvesting from vanilla orchids, mostly in Madagascar.
And just as demand for real vanilla is increasing, production is falling. With demand on the upswing, trade in the worlds most popular flavor is way out of balance, and getting worse.
Biology has an app for that
A few weeks ago, Boston-based biomanufacturing company Conagen and global chemical giant BASF announced a new partnership to address this problem. Conagen is lending BASF its expertise in fermentation, the ancient technique used in brewing beer and baking bread that uses microorganisms like bacteria or fungi to convert one substance into another. In this case, Conagen has cultivated a microbe that can take glucose and turn it into the valuable substance vanillin.
Fermented vanillin is the exact same molecule you would get from a vanilla bean. Fermentation has the added advantage of producing pure, reliable ingredients. And because the fermented product is equivalent to what you get from nature, it can be labeled natural flavoring.
With BASF, Conagen will help BASF scale up its vanillin fermentation process, which BASF will market for use in natural flavorings like chocolate, strawberry, and caramel. The partnership will strengthen BASFs biotechnology in the natural food and flavors ingredients market.
To understand why this is a big deal, you first have to understand who BASF is.
The biggest company youve never heard of
BASF is the largest chemical maker in the world, with 63 billion in revenues in 2018. Its based in Germany but has facilities all over the world, supplying companies in the pharmaceutical, construction, textile, and automotive industries with the chemical building blocks of modern industry. Most of us have never heard of these chemicals, or can even pronounce them, but all of us are probably familiar with one of BASFs 90,000 partners, including many well-known consumer brands.
Despite its size and global presence, BASF has a low public profile. Theres a great old marketing campaign circa 1991 that captures this very well: At BASF, we dont make a lot of the products you buy. We make a lot of the products you buy better.
If you ask me, synthetic biology is a lot like that: It doesnt necessarily change the kind of things you buy, its just making them greener, better, and less expensive. Conagen is just the latest example of how companies in this space are disrupting value chains and providing fully integrated solutions to others, making plug-and-play biomanufacturing possible.
The partnership is just one example of how companies like BASF no. 115 on the Fortune Global 500 are being transformed by the convergence of tech and bio and the growing bioindustrial revolution.
Vanillin is just a tiny example. There is a huge industrial demand for other flavors, such as orange (valencene) and grapefruit (nootkatone).
Then theres the fragrance industry, which relies on more exotic scents like musk (muscone), skunk (crotyi mercaptan), and ambergris (ambrox) to create those exquisite fragrance combinations we treasure at the perfume counter. In the old days, it was necessary to kill animals to obtain fragrance ingredients like musk. Thats now illegal, and the development of synthetic musks for the fragrance industry is credited with saving the musk deer from extinction.
Conagen is one of several companies working to meet the demand for natural flavors and fragrances. Many of the biggest flavors and fragrances companies (Firmenich, Givaudan, Robertet, and Takasago among them) are partnering with synthetic biology companies like Ginkgo Bioworks, Evolva, Amyris, and Conagen to produce sustainable ingredients.
This is bigger than food
And even though the entire flavors and fragrances market is estimated at over $20 billion,food is just one small area where synthetic biology can enable us to sustainably biomanufacture precision chemicals. The pharmaceutical industry stands to win, too.
For example, Conagen just launched a glycoprotein platform that could transform the immunotherapy and antibody-drug market the kind of drugs that help your native immune system better identify and respond to all sorts of diseases, including cancer. This is the category of drugs that includes monoclonal antibodies a market segment estimated at $100 billion alone.
Conagens biotechnology platform would reduce the time and capital to develop these drugs in the pharmaceutical industry. As a result, the technology would reduce costs, and patients reap the savings.
As synthetic biology drives down R&D costs and makes industrial scale-up cheaper and more agile, a new era of pharma will pursue a widening range of diseases beginning with so-called orphan diseases (affecting 200,000 or fewer people) and continuing to personalized medicine.
Smaller drug companies could also get in on the act.
As Conagen CEO Oliver Yu explained to me, The R&D at the bench level is only the first part of developing a product. Once you have developed a proof of concept, its a long way to go to get to the finished product. Over the past decade, Yu has built a vertically integrated team of experts in fermentation and industrial biomanufacturing that enable companies with a good idea to scale it to commercial levels.
Yu looks around and sees his industry becoming more product-oriented, and it's a good sign. There are companies making probiotics, there are companies using synthetic biology to treat disease, there are companies making DNA and RNA and enzymes to address specific illnesses and health concerns. So theres a lot we can do.
The focus of Conagen is always on the product, Yu said.
Industry trends in natural ingredients, and the cost of inaction
Companies that are slow to get on the natural ingredients bandwagon may pay a price. Take Johnson & Johnson, which reported a 20% decline in the sales of its flagship baby product brand, with its CFO stating that it looks like Millennial moms are trying a lot of new organic natural premium-type brands. It announced very robust plans to relaunch its 124-year-old brand.
Others who have been more sensitive to consumer demand have created their own sustainable product lines. In 2016 Procter & Gamble launched Tide Pureclean, which its CFO said already holds a 7% share of the pure and naturals segment and is driving over 150% of the natural segment growth. It recently went a step further in introducing EC30, a wafer-like replacement to liquid cleaners that stands to reduce carbon emissions on a global scale.
Keeping it real
Above all else, some experts believe that transparency and authenticity are key in the natural products market.
Consumers want to know exactly whats in their products and how they are made. They want to be empowered to make informed decisions for themselves about how well a product represents their lifestyle values. Consumer brands and biotechnology companies must understand those human values and strive to meet them as genuinely as possible, even in the face of our increasingly tech-driven world.
Synthetic biology is delivering consumers new choices that are more sustainable, more efficient, and less expensive. And who knows, they might just be more delicious.
Acknowledgement: Thank you to Kevin Costa for additional research and reporting in this post.
Please note: I am the founder ofSynBioBeta, and some of the companies that I write about, including Conagen, are sponsors of theSynBioBeta conference(click herefor a full list of sponsors).
The rest is here:
Better Than Nature: Why Fermenting Vanilla Is Good For Consumers, The Environment, And The Economy - Forbes
- Curt Medeiros on Revolutionizing Precision Medicine and Scaling Ovation - Madrona Venture Group - January 6th, 2025
- Personalized medicine: The pros, cons and concerns - New Atlas - November 16th, 2024
- Precision Medicine, AI, and the Future of Personalized Health Care - November 16th, 2024
- Why precision medicine results in more effective health care, treatment plans - The Business Journals - November 16th, 2024
- Comprehensive Genomic Profiling at Diagnosis Extends Survival in Patients with Advanced Cancer - Inside Precision Medicine - November 16th, 2024
- More Precise Classifications of NonClear Cell RCC Are Required to Improve Personalized Treatment - OncLive - September 13th, 2024
- Bahrain aims to provide residents with personalized healthcare - Healthcare IT News - September 13th, 2024
- Precision Medicine Market Is Expected To Reach Revenue Of - GlobeNewswire - September 13th, 2024
- New Graduates Leverage Genomics Education in Clinical and Research Settings - University of Colorado Anschutz Medical Campus - June 20th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022
- PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - 69News WFMZ-TV - June 8th, 2022
- BITS Pilani Hyderabad to conduct 'Precision Medicine 2022' event tomorrow - United News of India - June 8th, 2022
- Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026 - Yahoo Finance - June 8th, 2022
- Medical Nutrition Market Promising Growth Opportunities and Forecast 2027 - Digital Journal - June 8th, 2022
- 57% of Organizations in India are at the Startup Stage of Genomics High-Performance Computing Infrastructure - APN News - June 8th, 2022
- Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies - StreetInsider.com - June 8th, 2022
- Inspiration for the laboratory of tomorrow - Chemie.de - June 8th, 2022
- Global Nanomaterials in Personalized Medicine Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2022-2028 Queen Anne and Mangolia... - May 8th, 2022
- The global biomarkers market is expected to grow at a CAGR of 11.44%. - Yahoo Finance - May 8th, 2022
- Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular... - May 8th, 2022
- Link between EBV and MS may give clues to the cause of long COVID - The Arizona Republic - May 8th, 2022
- Improving Cell Cultures with Thermoresponsive Coatings - Genetic Engineering & Biotechnology News - May 8th, 2022
- Reevaluating, Reimagining, And Reinventing Healthcare: Innovation In A Post-Pandemic World - Forbes - May 8th, 2022
- Study of Cancer Genetics to Help with Targeted Treatment - VOA Learning English - May 8th, 2022
- Increased demand for Molecular diagnostics after the COVID-19 outbreak - The Financial Express - May 8th, 2022
- CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News - January 30th, 2022
- SeqOne Genomics Closes 20M Series a to Accelerate the Deployment of Its Genomic Medicine Platform - Business Wire - January 30th, 2022
- Study: In IBS patients, cognitive behavioral therapy modulates the brain-gut microbiome and helps relieve symptoms - UB News Center - January 30th, 2022
- (New Report) Digital Genome Market In 2022 : The Increasing use in Diagnostics, Agriculture & Animal Research, Personalized Medicine, Drug... - January 30th, 2022
- Silencing a faulty gene may uncover clues to rare forms of ALS - National Institutes of Health - January 30th, 2022
- Plants, Bioprinting and Orbital Plumbing Fill Crew's Thursday Schedule - NASA - January 30th, 2022